Takeda's Zasocitinib Shows Superiority in Psoriasis Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Success: Takeda Canada announced that its new drug, Zasocitinib, demonstrated significant efficacy in a Phase 3 trial for moderate-to-severe psoriasis, achieving a PASI 100 clearance rate of over 35%, which is more than 2.5 times that of the comparator drug, Deucravacitinib, highlighting its potential in psoriasis treatment.
- Multiple Endpoint Superiority: The study also showed statistical superiority for Zasocitinib across all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16, further solidifying its position as an effective treatment option.
- Good Safety Profile: Zasocitinib was generally well tolerated with no new safety signals identified, indicating its feasibility for clinical use and potentially attracting more patients to choose this medication.
- New Drug Application Plans: Takeda is on track to submit a New Drug Application for psoriasis to the U.S. FDA within this fiscal year, marking a significant advancement in market promotion and commercialization, which is expected to generate new revenue streams for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TAK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 16.960
Low
18.00
Averages
18.00
High
18.00
Current: 16.960
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insilico Medicine Partners with Takeda for AI-Driven Drug Development
- Deal Value: Insilico Medicine's partnership with Japanese pharmaceutical company Takeda is valued at up to $600 million, encompassing the discovery, development, and commercialization of drug candidates, highlighting the strong collaborative potential in the biopharmaceutical sector.
- Project Initiation Fees: Under the agreement, Insilico will receive approximately $60 million in project initiation fees, near-term payments, and milestone rewards, which not only provide financial support but also lay the groundwork for future R&D activities.
- AI-Driven Drug Discovery: Insilico will leverage its Pharma.AI platform to identify drug candidates within Takeda's therapeutic areas, while Takeda will lead the clinical advancement of molecules that meet scientific and early-development criteria, underscoring the significance of AI in the pharmaceutical industry.
- Strategic Transformation Support: This collaboration supports Takeda's transition to an AI-native discovery model, integrating automation, robotics, and generative AI to advance high-quality candidates more efficiently, reflecting the industry's emphasis on new technologies.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Takeda Appoints New CEO Julie Kim Amid Leadership Transition
- Leadership Change: Takeda Pharmaceutical announced the appointment of Julie Kim as the new CEO, completing an 18-month leadership transition that signifies a crucial shift in the company's strategic direction.
- Former CEO Retirement: Former CEO Christophe Weber has retired from both the company and the board, which may impact future decision-making and market performance for Takeda.
- Shareholder Election: Julie Kim was elected as an internal director at the annual shareholder meeting in Osaka and subsequently appointed as Representative Director, President, and CEO, indicating shareholder confidence in her leadership capabilities.
- Positive Market Reaction: On the Tokyo Stock Exchange, Takeda's shares rose by 1.86% during Tuesday's trading, closing at 5,104 Japanese Yen, reflecting market confidence in the new leadership team.
See More
Takeda Completes Leadership Transition with New CEO Appointment
- Leadership Change: Takeda has officially appointed Julie Kim as the new Representative Director, President, and CEO during the shareholder meeting, succeeding Christophe Weber after 12 years, marking the completion of an 18-month leadership transition that is expected to drive future growth strategies.
- New Board Members: Shareholders elected three high-profile external directors, including Paul Stoffels, former Chief Science Officer at Johnson & Johnson, who has overseen 25 global medicine launches, which is anticipated to enhance the company's innovation capacity and market competitiveness.
- Independent Board Composition: Takeda's board maintains a strong independent tilt, with eight out of 11 members being external directors, ensuring objectivity and transparency in decision-making processes, thereby improving corporate governance standards.
- Committee Structure: The Audit, Nomination, and Compensation committees will consist solely of external directors, a structure that will strengthen internal controls and risk management, ensuring the company adheres to high compliance standards in its future operations.
See More
Takeda Appoints New President
- Executive Appointment: Takeda Pharmaceutical announced on Wednesday the appointment of Julie Kim as the new President and CEO, aimed at strengthening the strategic direction and execution of the company's leadership.
- Leadership Experience: Julie Kim brings extensive management experience in the pharmaceutical industry, having held executive positions at several renowned pharmaceutical companies, and her addition is expected to enhance Takeda's competitiveness in the global market.
- Strategic Goals: The appointment of the new president reflects Takeda's focus on future growth, particularly in the areas of innovative drug development and market expansion.
- Market Reaction: Although the appointment did not trigger significant market fluctuations, analysts generally believe that the new leadership team will bring about positive changes for the company.
See More
Takeda Appoints Julie Kim as CEO Following Shareholder Vote
- Leadership Transition: Takeda officially appointed Julie Kim as Representative Director, President, and CEO during the Annual General Meeting, marking the completion of an 18-month CEO transition, which is expected to drive the launch of three new medicines in the next 12 months and enhance long-term shareholder value.
- New Board Members: Shareholders elected three new external directors, including Bruce Broussard, Koichiro Kimura, and Dr. Paul Stoffels, enhancing the board's diversity and expertise, which is anticipated to bring broader industry perspectives and governance experience to the company.
- Strategic Development Focus: Under Kim's leadership, Takeda will concentrate on advancing its innovative drug pipeline, particularly five late-stage assets, aiming to improve patient treatment outcomes and expand market share, thereby solidifying the company's position in the industry.
- Acknowledgment of Former Leadership: The board expressed gratitude for former CEO Christophe Weber's 12 years of extraordinary service, emphasizing his contributions to global scale and innovative pipeline, reflecting the company's commitment to leadership stability and ensuring continued growth in the future.
See More
Insilico Medicine Partners with Takeda for AI-Driven Drug Development
- Deal Value: Insilico Medicine's partnership with Japanese pharmaceutical company Takeda is valued at up to $600 million, encompassing the discovery, development, and commercialization of drug candidates, highlighting the strong collaborative potential in the biopharmaceutical sector.
- Project Initiation Fees: Under the agreement, Insilico will receive approximately $60 million in project initiation fees, near-term payments, and milestone rewards, which not only provide financial support but also lay the groundwork for future R&D activities.
- AI-Driven Drug Discovery: Insilico will leverage its Pharma.AI platform to identify drug candidates within Takeda's therapeutic areas, while Takeda will lead the clinical advancement of molecules that meet scientific and early-development criteria, underscoring the significance of AI in the pharmaceutical industry.
- Strategic Transformation Support: This collaboration supports Takeda's transition to an AI-native discovery model, integrating automation, robotics, and generative AI to advance high-quality candidates more efficiently, reflecting the industry's emphasis on new technologies.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Takeda Appoints New CEO Julie Kim Amid Leadership Transition
- Leadership Change: Takeda Pharmaceutical announced the appointment of Julie Kim as the new CEO, completing an 18-month leadership transition that signifies a crucial shift in the company's strategic direction.
- Former CEO Retirement: Former CEO Christophe Weber has retired from both the company and the board, which may impact future decision-making and market performance for Takeda.
- Shareholder Election: Julie Kim was elected as an internal director at the annual shareholder meeting in Osaka and subsequently appointed as Representative Director, President, and CEO, indicating shareholder confidence in her leadership capabilities.
- Positive Market Reaction: On the Tokyo Stock Exchange, Takeda's shares rose by 1.86% during Tuesday's trading, closing at 5,104 Japanese Yen, reflecting market confidence in the new leadership team.
See More
Takeda Completes Leadership Transition with New CEO Appointment
- Leadership Change: Takeda has officially appointed Julie Kim as the new Representative Director, President, and CEO during the shareholder meeting, succeeding Christophe Weber after 12 years, marking the completion of an 18-month leadership transition that is expected to drive future growth strategies.
- New Board Members: Shareholders elected three high-profile external directors, including Paul Stoffels, former Chief Science Officer at Johnson & Johnson, who has overseen 25 global medicine launches, which is anticipated to enhance the company's innovation capacity and market competitiveness.
- Independent Board Composition: Takeda's board maintains a strong independent tilt, with eight out of 11 members being external directors, ensuring objectivity and transparency in decision-making processes, thereby improving corporate governance standards.
- Committee Structure: The Audit, Nomination, and Compensation committees will consist solely of external directors, a structure that will strengthen internal controls and risk management, ensuring the company adheres to high compliance standards in its future operations.
See More
Takeda Appoints New President
- Executive Appointment: Takeda Pharmaceutical announced on Wednesday the appointment of Julie Kim as the new President and CEO, aimed at strengthening the strategic direction and execution of the company's leadership.
- Leadership Experience: Julie Kim brings extensive management experience in the pharmaceutical industry, having held executive positions at several renowned pharmaceutical companies, and her addition is expected to enhance Takeda's competitiveness in the global market.
- Strategic Goals: The appointment of the new president reflects Takeda's focus on future growth, particularly in the areas of innovative drug development and market expansion.
- Market Reaction: Although the appointment did not trigger significant market fluctuations, analysts generally believe that the new leadership team will bring about positive changes for the company.
See More
Takeda Appoints Julie Kim as CEO Following Shareholder Vote
- Leadership Transition: Takeda officially appointed Julie Kim as Representative Director, President, and CEO during the Annual General Meeting, marking the completion of an 18-month CEO transition, which is expected to drive the launch of three new medicines in the next 12 months and enhance long-term shareholder value.
- New Board Members: Shareholders elected three new external directors, including Bruce Broussard, Koichiro Kimura, and Dr. Paul Stoffels, enhancing the board's diversity and expertise, which is anticipated to bring broader industry perspectives and governance experience to the company.
- Strategic Development Focus: Under Kim's leadership, Takeda will concentrate on advancing its innovative drug pipeline, particularly five late-stage assets, aiming to improve patient treatment outcomes and expand market share, thereby solidifying the company's position in the industry.
- Acknowledgment of Former Leadership: The board expressed gratitude for former CEO Christophe Weber's 12 years of extraordinary service, emphasizing his contributions to global scale and innovative pipeline, reflecting the company's commitment to leadership stability and ensuring continued growth in the future.
See More
